AREV Life Sciences Global (CSE: AREV) (OTC: AREVF) has partnered with TransBIOTech, a publicly supported preclinical research organization, in a project to research cannabinoids and other early-stage commercial programs. TransBIOTech works with and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (“NSERC”) in collaboration with the Canadian Institutes of Health Research (“CIHR”). AREV and TransBIOTech will work together to establish a foundation for further research focused on specific understandings of the company’s recent chemical entity development including initial toxicity, pharmacokinetics and metabolism modeling essential for human studies and eventual commercialization. In addition, AREV also named a new chief operating officer. The company noted that Kevin Phelps, CPA and AREV board member, will be assuming the responsibilities of company COO. Phelps brings 40 years of biotech and general business expertise to the new role. He has served in a variety of executive positions, including as CEO, CFO and vice president of business development.
“TransBIOTech is engaging with AREV in its initial research on cannabinoids and other early-stage commercial research programs,” said AREV CEO Mike Withrow in the press release. “Our agreement with TransBIOTech signals the initiation of a robust clinical initiative with numerous collaborators to facilitate data on some of the more promising phytomedicinal therapeutics currently relevant to today’s public health challenges. AREV Life Sciences is determined to enhance our scientific acumen by partnering with dynamic programs that will facilitate breakthrough discoveries of therapeutic innovation relevant to contemporary pandemic infectious disease and human nutrition. By leveraging our proprietary extraction technologies paired with the discovery capacities of TransBIOTech and other well-respected research institutions, we are laying the groundwork for initial animal studies to identify data sets that will satisfy regulatory authorities.”
ABOUT AREV Life Sciences Global Corp.
AREV Life Sciences Global is a publicly traded, fully integrated, early-stage life science enterprise with a U.S. subsidiary dedicated to delivering therapeutic interventions to public health through extraction of unique compounds, discovery, innovation and successful collaborations. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and elevated inflammatory responses. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic comorbidities and innovations in human nutrition. In addition to its phytomedicinal discovery program, AREV is developing a next-generation Ready-to-Use Therapeutic Food (“RUTF”). SUSTAINN is designed by AREV in collaboration with the Richardson Centre for Functional Foods and Nutraceuticals at the University of Manitoba that demonstrates clinical attributes addressing serious acute malnutrition. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and the Biotechnology Innovation Organization. For more information about the company, please visit www.AREVLifeSciences.com
NOTE TO INVESTORS: The latest news and updates relating to AREVF are available in the company’s newsroom at https://ibn.fm/AREVF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork